Eyenovia Inc

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.